<?xml version="1.0" encoding="iso-8859-1" ?>
<rss version="2.0" xmlns:s="http://resources.bnet.com/">
<channel>
	<title><![CDATA[Vivus Inc. | Company News & Executive Profiles - VVUS | BNET]]></title>
	<link><![CDATA[http://resources.bnet.com/topic/vivus+inc..html?i=11]]></link>
	<description><![CDATA[Latest company news & analysis, recent events, stock quotes, earning call transcripts, with profiles and descriptions of top business executives for Vivus Inc.]]></description>
	<s:counts start="0" returned="10" found="17" />
	<language>en-us</language>
	<item>
		<title><![CDATA[Insider Selling at Vivus Not Yet Cause for Alarm]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F161565-insider-selling-at-vivus-not-yet-cause-for-alarm%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[Ruthanne Williams Roussel submits: There&#8217;s a good argument to be made that insider buys are a stronger predictor of stock movements than insider sales.  To boil it down, there are two basic reasons for this, which we can see by taking a look at Vivus Inc. VVUS as an...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_seekingalpha.gif" type="image/gif" />
		<pubDate>Tue, 15 Sep 2009 05:35:25 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/biotech.html"><![CDATA[Biotech]]></category>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/ruthanne+williams+roussel.html"><![CDATA[Ruthanne Williams Roussel]]></category>
		<category domain="http://resources.bnet.com/topic/vivus+inc..html"><![CDATA[Vivus Inc.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">VVUS</category>
		<category domain="tickers">VVUS</category>
	</item>
	<item>
		<title><![CDATA[Vivus's Qnexa Drug Approval Makes It a Nice Trade]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F160833-vivus-s-qnexa-drug-approval-makes-it-a-nice-trade%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[Here are Wednesday's articles concerning Vivus Inc's VVUS FDA approval for Qnexa. I see this as a blockbuster drug candidate and good news for the nearly 40M Obese Americans. My only caution is later health problems as it uses some form of the fen-phen medication. This is a nice trade...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_seekingalpha.gif" type="image/gif" />
		<pubDate>Thu, 10 Sep 2009 05:46:46 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/biotech.html"><![CDATA[Biotech]]></category>
		<category domain="http://resources.bnet.com/topic/biopharma+investor.html"><![CDATA[BioPharma Investor]]></category>
		<category domain="http://resources.bnet.com/topic/vivus+inc..html"><![CDATA[Vivus Inc.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">VVUS</category>
		<category domain="tickers">VVUS</category>
	</item>
	<item>
		<title><![CDATA[Vivus: Rumors of Huge Revenue Drop Greatly Exaggerated]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F153987-vivus-rumors-of-huge-revenue-drop-greatly-exaggerated%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[Ruthanne Williams Roussel submits: Vivus VVUS released a 10-Q for the second quarter Friday night, which caused some small excitement because of what appeared to be a huge year-over-year revenues drop but it should not have.   VVUS hardly has any cash revenues.  About $10 million of its...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_seekingalpha.gif" type="image/gif" />
		<pubDate>Wed, 05 Aug 2009 09:03:00 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/biotech.html"><![CDATA[Biotech]]></category>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/ruthanne+williams+roussel.html"><![CDATA[Ruthanne Williams Roussel]]></category>
		<category domain="http://resources.bnet.com/topic/vivus+inc..html"><![CDATA[Vivus Inc.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">VVUS</category>
		<category domain="tickers">VVUS</category>
	</item>
	<item>
		<title><![CDATA[Vivus: Still Undervalued]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F137057-vivus-still-undervalued%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[Ruthanne Williams Roussel submits: Vivus VVUS announced first quarter results and held a conference call, on which, uncharacteristically, there was only one question.  Essentially, the story has not changed, which is good: Top-line data from the pivotal Phase III EQUIP and CONQUER trials is expected in 3Q09The first Phase...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_seekingalpha.gif" type="image/gif" />
		<pubDate>Tue, 12 May 2009 01:45:07 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/biotech.html"><![CDATA[Biotech]]></category>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/ruthanne+williams+roussel.html"><![CDATA[Ruthanne Williams Roussel]]></category>
		<category domain="http://resources.bnet.com/topic/vivus+inc..html"><![CDATA[Vivus Inc.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">VVUS</category>
		<category domain="tickers">VVUS</category>
	</item>
	<item>
		<title><![CDATA[Four Weighty Reasons to Invest in Vivus]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F125309-four-weighty-reasons-to-invest-in-vivus%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[Ruthanne Williams Roussel submits:   If  Vivus's VVUS Qnexa proves as effective, well-tolerated and safe in pivotal Phase III trials as it so far has shown itself to be, then it has the potential to become a very successful obesity drug. by Ruthanne Williams Roussel]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_seekingalpha.gif" type="image/gif" />
		<pubDate>Wed, 11 Mar 2009 02:36:22 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/ruthanne+williams+roussel.html"><![CDATA[Ruthanne Williams Roussel]]></category>
		<category domain="http://resources.bnet.com/topic/arena+pharmaceuticals+inc..html"><![CDATA[Arena Pharmaceuticals Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/vivus+inc..html"><![CDATA[Vivus Inc.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">ARNA</category>
		<category domain="http://rss.financialcontent.com/stocksymbol">VVUS</category>
		<category domain="tickers">ARNA,VVUS</category>
	</item>
	<item>
		<title><![CDATA[VIVUS Inc. Q4 2008 Earnings Call Transcript]]></title>
		<link><![CDATA[http://www.bnet.com/2462-14055_23-277263.html]]></link>
		<description><![CDATA[ Question-and-Answer SessionOperator Operator Instructions Your first question comes from Jason Butler - Rodman & Renshaw. Jason Butler - Rodman & Renshaw  I was just wondering if you could give us some background on the methodology you&#8217;re using to assess changes in cognitive function in the EQUIP and CONQUER...]]></description>
		<s:doctype><![CDATA[Earnings calls]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_seekingalpha.gif" type="image/gif" />
		<pubDate>Mon, 09 Mar 2009 18:08:31 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/physician.html"><![CDATA[Physician]]></category>
		<category domain="http://resources.bnet.com/topic/call+transcript.html"><![CDATA[Call Transcript]]></category>
		<category domain="http://resources.bnet.com/topic/earnings.html"><![CDATA[Earnings]]></category>
		<category domain="http://resources.bnet.com/topic/population.html"><![CDATA[Population]]></category>
		<category domain="http://resources.bnet.com/topic/vivus+inc..html"><![CDATA[Vivus Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/federal+government.html"><![CDATA[Federal Government]]></category>
		<category domain="http://resources.bnet.com/topic/government.html"><![CDATA[Government]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://resources.bnet.com/topic/seeking+alpha.html"><![CDATA[Seeking Alpha]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">VVUS</category>
		<category domain="tickers">VVUS</category>
	</item>
	<item>
		<title><![CDATA[VIVUS Inc. Q2 2008 Earnings Call Transcript]]></title>
		<link><![CDATA[http://www.bnet.com/2462-14055_23-224697.html]]></link>
		<description><![CDATA[ Question-and-Answer SessionOperator Operator Instructions. Your first question comes from the line of Cory Kasimov from JPMorgan. Please proceed. Tim Morris Cory are you there? Operator Please unmute your line Mr. Kasimov. Tim Morris Operator, we can come back. Cory are you there? Cory Kasimov - JPMorgan Yeah, can you...]]></description>
		<s:doctype><![CDATA[Earnings calls]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_seekingalpha.gif" type="image/gif" />
		<pubDate>Mon, 04 Aug 2008 16:16:10 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/vivus+inc..html"><![CDATA[Vivus Inc.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">VVUS</category>
		<category domain="tickers">VVUS</category>
	</item>
	<item>
		<title><![CDATA[VIVUS Inc. Q1 2008 Earnings Call Transcript]]></title>
		<link><![CDATA[http://www.bnet.com/2462-14055_23-226331.html]]></link>
		<description><![CDATA[ Question-and-Answer SessionOperator Operator Instructions. And your first question comes from Corey Cosmo from JPMorgan. Please proceed. Corey Kasimov - JPMorgan Good afternoon. Thank you for taking the questions. I want to start with the upcoming Phase II data at ADA and obese diabetics and kind of start framing expectations...]]></description>
		<s:doctype><![CDATA[Earnings calls]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_seekingalpha.gif" type="image/gif" />
		<pubDate>Fri, 30 May 2008 07:56:11 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/vivus+inc..html"><![CDATA[Vivus Inc.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">VVUS</category>
		<category domain="tickers">VVUS</category>
	</item>
	<item>
		<title><![CDATA[VIVUS Inc. Q4 2007 Earnings Call Transcript]]></title>
		<link><![CDATA[http://www.bnet.com/2462-14055_23-228938.html]]></link>
		<description><![CDATA[ Question-and-Answer SessionOperator Operator Instructions First question comes from the line of Shar Yanni with JP Morgan, please proceed. Shar Yanni &#8211; JP Morgan Thank you so much for taking my call.  I had a couple questions.  First of all I wanted to know if the FDA draft...]]></description>
		<s:doctype><![CDATA[Earnings calls]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_seekingalpha.gif" type="image/gif" />
		<pubDate>Mon, 24 Mar 2008 15:40:10 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/vivus+inc..html"><![CDATA[Vivus Inc.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">VVUS</category>
		<category domain="tickers">VVUS</category>
	</item>
	<item>
		<title><![CDATA[Focus List.]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_hb5243/is_200707/ai_n19775107]]></link>
		<description><![CDATA[M2 PRESSWIRE-30 July 2007-Bullishalerts.com: Focus ListC1994-2007  M2 COMMUNICATIONS LTD    RDATE:30072007    Philadelphia, PA - Bullish Alerts is currently monitoring the  following Stocks: Move, Inc. (Nasdaq: MOVE), Extreme Networks (Nasdaq:  EXTR) and VIVUS, Inc. (Nasdaq: VVUS)    For a comprehensive report...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Mon, 30 Jul 2007 23:59:59 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/extreme+networks.html"><![CDATA[Extreme Networks]]></category>
		<category domain="http://resources.bnet.com/topic/government.html"><![CDATA[Government]]></category>
		<category domain="http://resources.bnet.com/topic/internet.html"><![CDATA[INTERNET]]></category>
		<category domain="http://resources.bnet.com/topic/nasdaq+stock+market+inc..html"><![CDATA[Nasdaq Stock Market Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/network.html"><![CDATA[network]]></category>
		<category domain="http://resources.bnet.com/topic/networking.html"><![CDATA[NETWORKING]]></category>
		<category domain="http://resources.bnet.com/topic/realtor.com.html"><![CDATA[Realtor.com]]></category>
		<category domain="http://resources.bnet.com/topic/villanova+university.html"><![CDATA[Villanova University]]></category>
		<category domain="http://resources.bnet.com/topic/vivus+inc..html"><![CDATA[Vivus Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">EXTR</category>
		<category domain="http://rss.financialcontent.com/stocksymbol">NDAQ</category>
		<category domain="http://rss.financialcontent.com/stocksymbol">VVUS</category>
		<category domain="tickers">EXTR,NDAQ,VVUS</category>
	</item>
</channel>
</rss>
